Humacyte, Inc. (NASDAQ:HUMA) Given Consensus Rating of “Buy” by Brokerages

Humacyte, Inc. (NASDAQ:HUMA) has been given a consensus recommendation of “Buy” by the eight brokerages that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation, six have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $11.71.

Several brokerages have weighed in on HUMA. D. Boral Capital reiterated a “buy” rating and issued a $25.00 target price on shares of Humacyte in a report on Monday. HC Wainwright initiated coverage on shares of Humacyte in a report on Wednesday, May 14th. They set a “buy” rating and a $4.00 target price on the stock. Benchmark cut their target price on shares of Humacyte from $17.00 to $14.00 and set a “buy” rating on the stock in a research report on Wednesday, May 14th. Finally, Wall Street Zen raised shares of Humacyte from a “sell” rating to a “hold” rating in a research report on Thursday, May 22nd.

Insider Transactions at Humacyte

In other news, CFO Dale A. Sander bought 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, April 10th. The stock was bought at an average price of $1.53 per share, with a total value of $30,600.00. Following the completion of the transaction, the chief financial officer now directly owns 40,600 shares of the company’s stock, valued at approximately $62,118. The trade was a 97.09% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Kathleen Sebelius bought 50,000 shares of the stock in a transaction on Tuesday, April 8th. The stock was purchased at an average price of $1.32 per share, with a total value of $66,000.00. Following the completion of the purchase, the director now owns 91,207 shares of the company’s stock, valued at $120,393.24. This represents a 121.34% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought a total of 83,993 shares of company stock valued at $118,224 in the last 90 days. Insiders own 5.10% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in HUMA. Columbia Advisory Partners LLC purchased a new stake in Humacyte in the first quarter valued at about $27,000. Hamilton Lane Advisors LLC purchased a new position in shares of Humacyte in the 1st quarter valued at approximately $37,000. Letko Brosseau & Associates Inc. acquired a new stake in Humacyte in the 1st quarter worth approximately $42,000. Vontobel Holding Ltd. purchased a new stake in Humacyte during the 4th quarter worth approximately $50,000. Finally, Petros Family Wealth LLC acquired a new position in Humacyte during the 4th quarter valued at approximately $50,000. 44.71% of the stock is currently owned by hedge funds and other institutional investors.

Humacyte Price Performance

Shares of HUMA stock opened at $2.54 on Thursday. The company has a market capitalization of $394.00 million, a P/E ratio of -1.90 and a beta of 2.00. The company’s 50-day simple moving average is $1.86 and its two-hundred day simple moving average is $3.19. Humacyte has a one year low of $1.15 and a one year high of $9.79.

Humacyte (NASDAQ:HUMA) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.09. The firm had revenue of $0.52 million during the quarter, compared to the consensus estimate of $0.46 million. On average, research analysts expect that Humacyte will post -1.27 EPS for the current fiscal year.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.